Revision history of "(A19_067_2015_0670020_1140) A19_067_2015_0670020" (Q2167489)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

7 March 2024

10 June 2023

26 April 2023

8 April 2023

6 July 2022

  • curprev 21:5121:51, 6 July 2022DG Regio talk contribs 56,831 bytes +37,621 Changed label, description and/or aliases in da, el, hr, ro, sk, mt, pt, fi, pl, sl, cs, lt, lv, bg, hu, ga, sv, et, nl, fr, de, es, and other parts: Adding translations: da, el, hr, ro, sk, mt, pt, fi, pl, sl, cs, lt, lv, bg, hu, ga, sv, et,

4 February 2022

25 January 2022

25 December 2021

24 December 2021

23 December 2021

3 November 2020

17 July 2020

9 June 2020

24 March 2020

23 March 2020

  • curprev 11:4511:45, 23 March 2020DG Regio talk contribs 10,175 bytes +1,285 Created claim: summary (P836): THE AIM OF THE PROJECT IS TO DEVELOP, AS AN ORPHAN DRUG, A HUMAN PLASMA CONCENTRATE THAT IS CAPABLE OF PREVENTING AND TREATING THE HAEMORRHAGES OF THE DEFICIENT PERSONS. TO THE CURRENT STATE? THERE IS NO PV BASED CONCENTRATE AVAILABLE ON THE MARKET AND THE ACUTE BLEEDING EPISODES OF PATIENTS WITH A DEFICIT IN THIS FACTOR ARE TREATED WITH FRESH FROZEN PLASMA SO AS TO KEEP PV BLOOD LEVELS ABOVE 20 %; TO THIS END OFTEN? 750 TO 1 000 ML OF LIQUIDS W...

20 March 2020

17 March 2020

12 March 2020